亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

A novel diagnostic method and therapeutic treatment of acute pulmonary inflammation

总结
Researchersat OSU have discovered a novel antibody that could constitute a new therapeuticmethod to restrict the pathogenesis of ALI/ARDS. In a clinically relevantanimal model of ALI, a novel monoclonal antibody discovered by the researcherssignificantly inhibits neutrophil influx into alveolar space. Becauseneutrophil inflammation is central to development of ALI, this antibody mayprove to be the therapeutic agent that is greatly needed for ALI/ARDS patients.Moreover, this anitibody could be used as a novel diagnostic marker forALI/ARDS. This is critical because current diagnosis of ALI/ARDS is performedby the presence of non-cardiogenic pulmonary edema and respiratory failure,which are non-specific measures subject to inter-observer variability.
技术优势
·       Enables earlydetection of ALI/ARDS·       Novel treatmentmethod to reduce severity of ALI/ARDS
技术应用
·       Quantitativediagnostic tool for ALI/ARDS·       Method oftreatment for ALI/ARDS·       Treatment forother inflammatory diseases, especially lung
详细技术说明
None
*Abstract
None
*Background
Acute lung injury (ALI) and its severe form, acute respiratorydisease syndrome (ARDS), are life-threatening diseases with a variety ofcauses, including sepsis, trauma, and pneumonia. ALI and ARDS are characterizedby pulmonary endothelial and epithelial injury, and loss of the alveolarcapillary barrier with an influx of inflammatory cells. The incidence isestimated at 1.5 to 75 cases per 100,000 individuals and affects approximately190,000 Americans annually, with mortality rates ranging from 25% to 40%.  The current treatment approach to ALI/ARDSrelies on ventilator and cardiovascular support. However, In spite of thesetreatments, unacceptable morbidity and mortality remain in ALI/ARDS patients. Thereis a great need for novel pharmacological therapeutics that can help reduce themorbidity and permanent lung tissue damage associated with ALI/ARDS.
*Stage of Development
Proof of concept stage.
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备